Reviewer's report
Title:Rifaximin for maintenance therapy in antibiotic-dependent pouchitis
Version: 2Date:24 March 2008
Reviewer: Darrell S Pardi
Reviewer's report:
The authors have satisfactorily addressed my comments. The only additional
comment I have is in reference to the figure they have submitted in response to
Reviewer #1. Therein, they suggest that secondary causes of pouch symptoms
be excluded if a patient does not respond to a 4 week course of dual antibiotics
(or after not responding to a total of 8 weeks of therapy). I think that is too long to
let a patient go before evaluating for secondary causes, especially given the fact
that most patients with pouchitis respond well to antibiotics. Thus, i would
suggest that they move "Exclusion of secondary causes" up a few lines, before
the "cipro + metronidazole...." line.
What next?: Accept after discretionary revisions
Level of interest: An article whose findings are important to those with closely
related research interests
Quality of written English: Acceptable
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
I have previously performed consulting work for Salix, and am currently
participating in a clinical trial using rifaximin for the treatment of C. difficile
infection.
Reviewer's report
Title:Rifaximin for maintenance therapy in antibiotic-dependent pouchitis
Version: 2Date:24 March 2008
Reviewer: Darrell S Pardi
Reviewer's report:
The authors have satisfactorily addressed my comments. The only additional
comment I have is in reference to the figure they have submitted in response to
Reviewer #1. Therein, they suggest that secondary causes of pouch symptoms
be excluded if a patient does not respond to a 4 week course of dual antibiotics
(or after not responding to a total of 8 weeks of therapy). I think that is too long to
let a patient go before evaluating for secondary causes, especially given the fact
that most patients with pouchitis respond well to antibiotics. Thus, i would
suggest that they move "Exclusion of secondary causes" up a few lines, before
the "cipro + metronidazole...." line.
What next?: Accept after discretionary revisions
Level of interest: An article whose findings are important to those with closely
related research interests
Quality of written English: Acceptable
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
I have previously performed consulting work for Salix, and am currently
participating in a clinical trial using rifaximin for the treatment of C. difficile
infection.
Please review this paper.
user
Reviewer's report
Title:Rifaximin for maintenance therapy in antibiotic-dependent pouchitis
Version: 2Date:24 March 2008
Reviewer: Darrell S Pardi
Reviewer's report:
The authors have satisfactorily addressed my comments. The only additional
comment I have is in reference to the figure they have submitted in response to
Reviewer #1. Therein, they suggest that secondary causes of pouch symptoms
be excluded if a patient does not respond to a 4 week course of dual antibiotics
(or after not responding to a total of 8 weeks of therapy). I think that is too long to
let a patient go before evaluating for secondary causes, especially given the fact
that most patients with pouchitis respond well to antibiotics. Thus, i would
suggest that they move "Exclusion of secondary causes" up a few lines, before
the "cipro + metronidazole...." line.
What next?: Accept after discretionary revisions
Level of interest: An article whose findings are important to those with closely
related research interests
Quality of written English: Acceptable
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
I have previously performed consulting work for Salix, and am currently
participating in a clinical trial using rifaximin for the treatment of C. difficile
infection.
assistant